Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Literature DB >> 6849771

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

L Bertilsson, A Aberg-Wistedt.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1983 PMID： 6849771 PMCID： PMC1427780 DOI： 10.1111/j.1365-2125.1983.tb01518.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

7 in total

1. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins.

Authors: B Alexanderson
Journal: Eur J Clin Pharmacol Date: 1973-06 Impact factor: 2.953

2. A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man.

Authors: W Hammer; S Mårtens; F Sjöqvist
Journal: Clin Pharmacol Ther Date: 1969 Jan-Feb Impact factor: 6.875

3. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors: L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal: Eur J Clin Pharmacol Date: 1980-02 Impact factor: 2.953

4. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors: B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875

5. Active metabolites of imipramine and desipramine in man.

Authors: W Z Potter; H M Calil; T A Sutfin; A P Zavadil; W J Jusko; J Rapoport; F K Goodwin
Journal: Clin Pharmacol Ther Date: 1982-03 Impact factor: 6.875

6. Polymorphic hydroxylation of Debrisoquine in man.

Authors: A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal: Lancet Date: 1977-09-17 Impact factor: 79.321

7. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. I. Clinical findings.

Authors: A Aberg-Wistedt
Journal: Acta Psychiatr Scand Date: 1982-07 Impact factor: 6.392

7 in total

29 in total

1. Inhibitors of imipramine metabolism by human liver microsomes.

Authors: E Skjelbo; K Brøsen
Journal: Br J Clin Pharmacol Date: 1992-09 Impact factor: 4.335

2. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors: E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal: Eur J Clin Pharmacol Date: 1997 Impact factor: 2.953

9. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.

Authors: Kari Laine; Steven De Bruyn; Harry Björklund; Juha Rouru; Jutta Hänninen; Harry Scheinin; Markku Anttila
Journal: Eur J Clin Pharmacol Date: 2004-01-17 Impact factor: 2.953

Review 10. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors: C Nordin; L Bertilsson
Journal: Clin Pharmacokinet Date: 1995-01 Impact factor: 6.447

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

1. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins.

2. A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man.

3. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

4. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

5. Active metabolites of imipramine and desipramine in man.

6. Polymorphic hydroxylation of Debrisoquine in man.

7. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. I. Clinical findings.

1. Inhibitors of imipramine metabolism by human liver microsomes.

2. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

3. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

4. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.

5. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

6. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

7. Sparteine oxidation polymorphism: a family study.

8. Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

9. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.

Review 10. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.